tamrintamab pamozirine (SC-003) / AbbVie - LARVOL DELTA

Molecular Characterization of Clostridium botulinum Isolates from Sichuan Province, China (1990-2024). (PubMed, Foodborne Pathog Dis) - "All strains belonging to Group I (SC001, SC002, SC003, SC006, and SC009) were assigned to five totally different recognized ST types (ST-2 to ST-51). In addition, analysis of BoNTs subtypes demonstrated that the types of BoNTs causing botulism in Sichuan were mainly types A, B, and E. Among them, some rare subtypes of BoNT reported for the first time in China, such as BoNT/B4, BoNT/E12, and BoNT/A5(B3), and no specific subtypes were predominant in the botulism incidents. This study is critical for disease surveillance and early warning systems, while also providing a basis for food safety regulation, clinical diagnosis, and treatment in the future."

Journal

SC003 - Tough Cases/controversies in Stroke Neurocritical Care (ISC 2022) - "This will be a Case Discussion educational program with 2 discussants per case and a moderator. Each case will be 20 minutes total with various issues presented and then a 20 minute networking session."

Clinical • Cardiovascular

"SC-003 in ovarian cancer. #gyncsm https://t.co/Qppy8ZpT85" (@ErikaHamilton9)

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. (PubMed, Gynecol Oncol) - P1a/1b | "SC-003 lacked the requisite safety profile and antitumor activity to warrant further development."

Clinical • IO Biomarker • Journal • P1 data • Fatigue • Gynecologic Cancers • Oncology • Ovarian Cancer • Pain • Solid Tumor

Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity. (PubMed, J Struct Biol) - P1a/1b | "Hence DPEP3, unlike DPEP1 and DPEP2, may require an activating co-factor in vivo or may remain an inactive, degenerate enzyme. This report sheds light on the structural discriminants between active and inactive membrane dipeptidases and provides a benchmark to characterize current and future DPEP3-targeted therapeutic approaches."

Journal • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (clinicaltrials.gov) - P1a/1b; N=74; Terminated; Sponsor: Stemcentrx; Trial completion date: Jan 2020 ➔ Jan 2019; Active, not recruiting ➔ Terminated; Trial primary completion date: Jan 2020 ➔ Jan 2019; Strategic Considerations

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Trial termination